Cargando…

Telavancin in Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP) Caused by Staphylococcus aureus: Post Hoc Analysis of 2 Randomized, Controlled Trials

INTRODUCTION: The efficacy and safety of telavancin versus vancomycin in microbiologically evaluable patients with hospital-acquired or ventilator-associated pneumonia (HAP/VAP) caused by Staphylococcus aureus with vancomycin minimum inhibitory concentration (MIC) ≥ 1.0 µg/mL was analyzed using data...

Descripción completa

Detalles Bibliográficos
Autores principales:	Niederman, Michael S., Lee, Patrick C., Barriere, Steven L., Barnes, Chris N., Castaneda-Ruiz, Bibiana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702499/ https://www.ncbi.nlm.nih.gov/pubmed/31372837 http://dx.doi.org/10.1007/s40121-019-0255-0

Ejemplares similares

Clinical utility of telavancin for treatment of hospital-acquired pneumonia: focus on non-ventilator-associated pneumonia
por: Rubinstein, Ethan, et al.
Publicado: (2014)

Telavancin for the treatment of hospital-acquired pneumonia in severely ill and older patients: the ATTAIN studies
por: Rubinstein, E, et al.
Publicado: (2009)

Telavancin in the Treatment of Concurrent Staphylococcus aureus Bacteremia: A Retrospective Analysis of ATLAS and ATTAIN Studies
por: Wilson, Samuel E., et al.
Publicado: (2017)

Clinical Experience with Telavancin: Real-World Results from the Telavancin Observational Use Registry (TOUR™)
por: Bressler, Adam M., et al.
Publicado: (2019)

2364. Evaluation of Renal Function Changes in Patients With Prolonged Telavancin Therapy (>21 Days): Results From the Telavancin Observational Use Registry (TOUR™)
por: Hassoun, Ali, et al.
Publicado: (2018)

Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens
por: Rubinstein, Ethan, et al.
Publicado: (2011)

2369. Clinical Experience With Telavancin for Treatment of Patients With Monomicrobial S. aureus Infections (Vancomycin MIC ≥1 μg/mL) From TOUR™
por: Jacobs, Micah, et al.
Publicado: (2018)

Telavancin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA)
por: Hooper, Candace Y, et al.
Publicado: (2012)

Potential Role for Telavancin in Bacteremic Infections Due to Gram-Positive Pathogens: Focus on Staphylococcus aureus
por: Corey, G. Ralph, et al.
Publicado: (2015)

Metagenomics for the microbiological diagnosis of hospital-acquired pneumonia and ventilator-associated pneumonia (HAP/VAP) in intensive care unit (ICU): a proof-of-concept study
por: Heitz, Morgane, et al.
Publicado: (2023)

Assessment of Minimum Inhibitory Concentrations of Telavancin by Revised Broth Microdilution Method in Phase 3 Hospital-Acquired Pneumonia/Ventilator-Associated Pneumonia Clinical Isolates
por: Smart, Jennifer I., et al.
Publicado: (2016)

Clinical Experience with Telavancin for the Treatment of Patients with Bone and Joint Infections: Preliminary Results from the Telavancin Observational Use Registry (TOUR™)
por: Sims, Charles, et al.
Publicado: (2017)

Clinical Experience with Telavancin for the Treatment of Patients with Bacteremia and Endocarditis: Real-World Results from the Telavancin Observational Use Registry (TOUR™)
por: Reilly, Joseph, et al.
Publicado: (2020)

Real-World Clinical Use and Outcomes of Telavancin for the Treatment of Bone and Joint Infections: Results from the Telavancin Observational Use Registry (TOUR™)
por: Sims, Charles R., et al.
Publicado: (2021)

A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study
por: Stryjewski, Martin E, et al.
Publicado: (2014)

Use of a ventilator-associated pneumonia (VAP) bundle to decrease the VAP rate in Syria
por: Alsadat, R, et al.
Publicado: (2012)

354. A Comparison of Different Strategies for Optimizing the Selection of Empiric Antibiotic Therapy for Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP) Caused by Gram-Negative Bacteria in Intensive Care Units (ICU)
por: Wangchinda, Walaiporn, et al.
Publicado: (2023)

The effect of lactulose in prevention of ventilator associated pneumonia (VAP)
por: Zvonicek, V, et al.
Publicado: (2001)

Surveillance tracheal aspirate in ventilator associated pneumonia (VAP)
por: Lampati, L, et al.
Publicado: (2001)

Efficacy of telavancin for treatment of surgical site infections
por: Wilson, SE, et al.
Publicado: (2008)

Update on the emerging role of telavancin in hospital-acquired infections
por: Nnedu, Obinna N, et al.
Publicado: (2015)

Epidemiology of ventilator associated pneumonia (vap) in patients with abdominal sepsis
por: Hom Choudhuri, A, et al.
Publicado: (2015)

Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment
por: Worboys, Philip D., et al.
Publicado: (2015)

Mortality, incidence, and microbiological documentation of ventilated acquired pneumonia (VAP) in critically ill patients with COVID-19 or influenza
por: Laurichesse, Guillaume, et al.
Publicado: (2023)

Empiric Treatment in HAP/VAP: “Don’t You Want to Take a Leap of Faith?”
por: Chaïbi, Khalil, et al.
Publicado: (2022)

Analysis of Phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure
por: Torres, A., et al.
Publicado: (2014)

The zero-VAP sophistry and controversies surrounding prevention of ventilator-associated pneumonia
por: Colombo, Sebastiano Maria, et al.
Publicado: (2019)

Assessment of knowledge and implementation practices of the ventilator acquired pneumonia (VAP) bundle in the intensive care unit of a private hospital
por: Abad, Cybele Lara, et al.
Publicado: (2021)

Evidence supporting recommendations from international guidelines on treatment, diagnosis, and prevention of HAP and VAP in adults
por: Campogiani, Laura, et al.
Publicado: (2019)

The influence of enteral feeding on ventilator associated pneumonia (VAP) in trauma mechanically ventilated patients in ICU
por: Djazmati, W, et al.
Publicado: (2001)

Use of Adaptive Support Ventilation (ASV) in Ventilator Associated Pneumonia (VAP) - A Case Report
por: Kath, Bipphy, et al.
Publicado: (2009)

Activity of Telavancin against Staphylococcus aureus Isolates, Including Those with Decreased Susceptibility to Ceftaroline, from Cystic Fibrosis Patients
por: Roch, Melanie, et al.
Publicado: (2018)

Update of the activity of telavancin against a global collection of Staphylococcus aureus causing bacteremia, including endocarditis (2011–2014)
por: Mendes, R. E., et al.
Publicado: (2017)

Community-acquired pneumonia
por: Niederman, Michael S.
Publicado: (2010)

Microbiological study of ventilator-associated pneumonia (VAP) after implantation of pneumonia program zero (NZ)
por: Fernández Fernández, R, et al.
Publicado: (2015)

Higher clinical success in patients with ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus treated with linezolid compared with vancomycin: results from the IMPACT-HAP study
por: Peyrani, Paula, et al.
Publicado: (2014)

A Defensin from the Model Beetle Tribolium castaneum Acts Synergistically with Telavancin and Daptomycin against Multidrug Resistant Staphylococcus aureus
por: Rajamuthiah, Rajmohan, et al.
Publicado: (2015)

Implementing national guidelines in intensive care patients with ventilator-associated, hospital-acquired, and healthcare-associated pneumonia: the IMPACT-HAP project
por: Kett, DH, et al.
Publicado: (2008)

Pneumonia associated with mechanical ventilation (VAP): influence on morbidity and mortality in critically ill patients
por: Lucena, JG, et al.
Publicado: (2001)

Non-infectious approach to ventilator-associated pneumonia (VAP) in neonates: a new concept
por: Bejeh Mir, Karim Poorsattar, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_bc2q118mgkru07kahg98kp0fuo